Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.
Selonsertib did not improve liver fibrosis more than a placebo.
Curing the virus was associated with a lower risk of liver cancer recurrence.
These drugs are approved to treat all six major genotypes of hepatitis C.
The HepConnect initiative aims to expand testing, harm reduction and health care infrastructure.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
The subscription-based model is the first of its kind.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.